Study Raises Doubts Regarding Medical Marijuana.
The Los Angeles Times (6/24, Kaplan, 4.03M) reports in “Science Now” that researchers reviewed studies testing the effectiveness of medical marijuana on 10 different conditions and concluded that “there’s very little reliable evidence to support the drug’s use.” The review was published Tuesday in the Journal of the American Medical Association. While the review found “moderate-quality evidence” for the use of medical marijuana to treat “chronic neuropathic pain or cancer pain,” it also found that “trials testing the pain-relieving effects of medical marijuana in people with fibromyalgia, HIV-associated sensory neuropathy, rheumatoid arthritis, multiple sclerosis and other conditions did not show that it worked.”
According to CBS News (6/23, Welch, 8.2M), the JAMA study also found “an increased risk of adverse side effects, including dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination.”
Study: Labels For Edible Marijuana Products Largely Inaccurate About Potency. In a related story, the New York Times (6/24, A12, Saint Louis, Subscription Publication, 12.24M) reports that “an analysis of 75 edible marijuana products sold to patients in Seattle, San Francisco and Los Angeles found that labels on just 17 percent accurately described their levels of THC, the main psychoactive ingredient,” according to a study published Tuesday in the Journal of the American Medical Association. Researchers found that “sixty percent of the products had less THC than their packages advertised, and 23 percent of them had more THC than claimed.” Inaccurate labels can “complicate the consumption of marijuana for medical purposes,” because high variance in THC can either fail to relieve symptoms or overwhelm users.
The Seattle Times (6/24, Young, 970K) reports that the study found that samples taken from San Francisco and Seattle “tended to be weaker than labeled,” while “Los Angeles samples tended to be stronger than labeled.”
Also covering the story are the Washington Post (6/24, Chokshi, 5.03M), USA Today (6/24, Hughes, 5.01M), HealthDay (6/24, Thompson, 16K), the NPR (6/23, Yang, 1.52M) “Shots” blog, and Forbes (6/24, Kroll, 6.84M).